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The coronary arteries have been regarded as end arteries for decades. However, there are functionally relevant
anastomotic vessels, known as collateral arteries, which interconnect epicardial coronary arteries. These vessels provide
an alternative source of blood supply to the myocardium in cases of occlusive coronary artery disease. The relevance of
these collateral arteries is a matter of ongoing debate, but increasing evidence indicates a relevant protective role in
patients with coronary artery disease. The collateral circulation can be assessed by different methods; the gold standard
involves intracoronary pressure measurements. While the first clinical trials to therapeutically induce growth of collateral
arteries have been unavailing, recent pilot studies using external counterpulsation or growth factors such as
granulocyte colony stimulating factor (G-CSF) have shown promising results.
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Anastomotic channels, known as collateral vessels, con-
nect a territory supplied by one epicardial coronary artery
with that supplied by another [1]. Collateral arteries there-
fore provide an alternative source of blood supply to myo-
cardium that has been jeopardized by occlusive coronary
artery disease, and they can help to preserve myocardial
function in the setting of coronary artery disease [2]
(Figure 1).
While their growth is often thought to be initiated by
ischemia, collateral arteries are also present in individ-
uals who do not have coronary disease [2,3]. Obviously,
other factors seem to play a more important role.
Although collateral blood flow after epicardial coronary
occlusion may be sufficient in some patients to meet myo-
cardial needs at rest, the prevalent view is that collateral
circulation is generally not sufficient to meet myocardial
demands during exercise [4] and may not prevent myocar-
dial ischemia during coronary occlusion. To prevent myo-
cardial ischemia during acute vessel occlusion, a flow of
20% to 25% is generally regarded as sufficient to provide
the blood supply needed at rest [5]. One in four patients
without coronary artery disease has sufficient collaterals as
compared with one in three patients with coronary artery* Correspondence: pascalmeier74@gmail.com
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but genetic factors are likely to play a role [7-9].Assessing the collateral circulation
How can collateral function be measured? Except for the
situation with a known chronic total coronary occlusion,
there is currently no technique to quantify the collateral
circulation non-invasively in human. The easiest strategy
is the visual assessment of collateral arteries by coronary
angiography. This can be performed in a semiquantitative
manner as described by Rentrop et al. [10]. The Rentrop
method involves balloon occlusion of the contralateral
coronary artery, which is rarely performed. Collateral ves-
sels from patent to occluded are classified ranging from
grade 0 (no visible filling of any collateral channel), grade
1 (filling of the side branches of the occluded artery, with
no dye reaching the epicardial segment), grade 2 (partial
filling of the epicardial vessel), and grade 3 (complete fill-
ing of the epicardial vessel by collaterals) [11].
Instead, most clinicians and investigators apply the
Rentrop score without occluding the contralateral vessels.
However, a patent contralateral coronary artery increases
the back pressure in this collateral-receiving territory,
which underestimates the degree of collateralization. This
visual method has several other limitations: it is not a very
objective measure, and it is influenced by blood pressure
and the force of contrast injection as well as the duration
of filming.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Schematic drawing of the coronary artery circulation
with (left panel) and without (right panel) interarterial
anastomoses between the right coronary artery and the
occluded left anterior descending artery (LAD; occluded
beyond the third diagonal branch). The gray area indicates the
area at risk for myocardial infarction in case of the LAD occlusion
and in the absence of collaterals (corresponding to the infarct size in
the example on the right side). (Illustration by Anne Wadmore,
Medical Illustrations Ltd, London, UK).
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sures the so-called collateral flow index (CFI). Two
methods are available: one is based on Doppler velocity
measurements, which is limited by frequent artifacts. The
second one is more accurate and based on pressure meas-
urement. For the Doppler approach, the collateralization of
a certain coronary artery can be measured by placement of
a Doppler sensor tipped guide wire. Then, the antegrade
flow through the coronary artery needs to be blocked with
an angioplasty balloon. The flow velocity measured with
the Doppler sensor distal to the occluded vessel derives
from collaterals. Then, the vessel is angioplastied so that
there is no remaining lesion and the flow velocity mea-
sured again, which represents the flow through the normal
vessel. The collateral flow velocity is then compared to the
flow velocity through the open coronary artery and indi-
cates the percentage of normal blood flow that can be pre-
served via the collateral circulation in case of an abrupt
vessel occlusion [12].Table 1 Clinical factors that can influence collaterals
Factor (reference) Remarks
Degree of coronary stenosis
[16]
Strongest predictor, confirmed in several
studies





In patients with chronic total occlusions
Heart rate (lower) [15] Only in patients without coronary artery
diseasePressure-based CFI
The pressure index of the distal pressure during vessel oc-
clusion divided by the systemic blood pressure both
subtracted by central venous pressure measures a pressure-
derived CFI. The central venous pressure has to be taken
into account as a back pressure [2]. Another, simpler,
cheaper and very accurate way to measure collateral func-
tion is an intracoronary electrocardiogram (ECG) [5]. Stud-
ies have defined a threshold of ST-segment elevation ≥0.1
mV during a 1 to 2 minute vessel occlusion with an angio-
plasty balloon to define insufficient collateralization. In
addition, if the patient develops chest pain during balloonocclusion of the vessel, this can be regarded as a sign of in-
sufficient collateral function.
All three methods, Rentrop score, CFI and intracranial
ECG, predict clinical outcomes and are therefore useful
[5,13]. For research purposes, the CFI is clearly superior
because it is a continuous value while the Rentrop score
is an ordinal and the ECG a dichotomous variable. The
CFI is therefore more informative and increases the stat-
istical power.
Other methods have been described, such as ‘wash-out
collaterometry’ whereby the time to contrast dye clear-
ance distal to a balloon occluded artery is measured.
The washout is quicker the better the vessel is collateral-
ized [14]. However, in contrast to the above-mentioned
methods, none of these have shown a predictive value in
clinical practice.
Determinants of the collateral circulation
The degree of collateralization varies considerably among
patients. For many years, ischemia has been believed to be
the underlying stimulus for collateral growth. However, no
study could directly prove a causative role for ischemia in
the induction of collateral growth.
Clinical studies have described several independent clin-
ical and angiographic variables that correlate with the de-
gree of collateralization. In healthy individuals, these
include hypertension and resting heart rate [15], while vari-
ables in patients with coronary artery disease include sever-
ity of coronary stenosis [6,16], longer duration of angina
[16], proximal lesion location [16], and longer duration of
lesion occlusion [17] (Table 1).
Mechanism of collateral growth (arteriogenesis)
The most important trigger for collateral growth, called
arteriogenesis, is tangential fluid shear stress at the endo-
thelial level along with recruitment of bone marrow de-
rived mononuclear cells [2,18-20] (Figure 2). Following
obstruction or occlusion of a major artery, a steep pres-
sure gradient develops across the pre-existing collateral
anastomoses. This pressure gradient is the driving force
for an increase in blood flow through the collateral arteri-
oles, leading to an augmented fluid shear stress that, in
Figure 2 Mechanism of induction of collateral growth (arteriogenesis). (1) Endothelium senses shear stress via Ca+ channels, transduction
via glycocalyx and cytoskeleton. (2) Actin-binding Rho-activating protein (ABRA) and early growth response protein 1 (EDGR1) genes are
upregulated. (3) Activated endothelium expresses adhesion molecules such as intercellular adhesion molecule (ICAM) and growth factors such as
monocyte chemoattractant protein 1 (MCP1) as well as NO. (4) Circulating monocytes bind their macrophage 1 antigen (Mac-1) receptors to
ICAM. (5) Monocytes differentiate into macrophages and secrete additional growth factors and chemoattractants, stimulating proliferation of
smooth muscle and endothelial cells. (Illustration by Anne Wadmore, Medical Illustrations Ltd).
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exact way by which the collateral endothelial cell senses
the shear stress is still unrevealed. ‘Mechanosensation’ is a
multifactorial process, and it is currently accepted that not
only certain mechanosensitive channels on the endothelial
surface are needed to convert the physical force into a cel-
lular response, but that rather the cell as a whole, includ-
ing its cytoskeleton [21], and the endothelial glycocalyx
[22] acts as a mechanosensor [23]. There are, however, cer-
tain cation channels on the cell surface that are regarded to
be direct receptors for mechanical forces (for example,
shear stress: activated endothelium can, in turn, further set
off the process of arteriogenesis). Cell adhesion molecules
(intercellular adhesion molecule 1 (ICAM1), vascular cell
adhesion molecule 1 (VCAM1)) are upregulated to facili-
tate adhesion of circulating mononuclear cells. Crosstalk
with adjacent smooth muscle cells leads to the production
of nitric oxide (NO) and other pro-arteriogenic molecules.
Apart from tangential fluid shear stress, cyclic stress of the
collateral arteriole poses another means of activating the
endothelium and increasing collateral proliferation. Here,
signal transduction runs via activator protein 1, among
others [24].
The understanding of the physical processes of shear
stress and its strong influence on collateral artery growth
has led to the investigation of artificial models of excessive
shear stress. In a femoral arteriovenous shunt animal
model, where a surgical anastomosis was created between
the femoral artery and vein distal to the occlusion of thefemoral artery strongly lowered distal pressure (equaling
venous pressure), thus increased pressure gradient, shear
stress and finally collateral artery growth [19]. The blood
flow restoration following femoral artery occlusion in this
model exceeded 100% (of the contralateral, non-ligated
side) easily, demonstrating that collateral arterial blood
flow can actually surpass blood flow in the healthy circula-
tion. To dissect the molecular mechanism of shear stress
inducted stimulation of collateral artery growth a whole
genome expression analysis from developed collateral ar-
teries in the rabbit hindlimb was performed. Genome-wide
profiling revealed actin-binding Rho-activating protein
(ABRA) as one of the players most strongly upregulated
and therefore potentially with a strong causal role in
arteriogenesis. Indeed, overexpression and knockout exper-
iments confirmed the pro-arteriogenic role of ABRA [18].
Further research on the exact molecular mediators of shear
stress revealed the calcium channel TrpV4 to be induced
by shear stress and its physical or pharmacologic activation
to stimulate arteriogenesis [25]. Following complex signal-
ing mechanisms that are beyond the scope of the present
review gene expression and post-transcriptional modula-
tion in the endothelial cell are altered and lead to en-
hanced activation and expression of nitric oxide synthases
(NOS2 and NOS3), which both not only cause vasodilata-
tion but also stimulate collateral arterial proliferation and
growth [25,26].
These molecular changes lead to a local attraction and
activation of peripheral blood monocytes. They are the
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monocytes transmigrate through the endothelium; they
become activated and secrete matrix-degrading products
such as matrix metalloproteinases (MMPs), leading to out-
ward arterial remodeling. They also release other cyto-
kines that orchestrate the process of arteriogenesis. For
example, chemoattractants for further monocytes such as
monocyte chemoattractant protein 1 (MCP-1), mitogenic
factors leading to smooth muscle cell proliferation such as
platelet-derived growth factor (PDGF) and tumor necrosis
factor α (TNFα). The latter promotes collateral formation
via its p55 receptor, as has been demonstrated in a knock-
out model in mice [27].
In addition, it has been debated whether pluripotent
bone-marrow-derived stem cells homing to endothelium
may give rise to formation of new vascular wall compo-
nents [28]. Recruitment of these circulating progenitor cells
(regulated by nitric oxide/reactive oxygen species balance)
may relate to the molecular basis of collateral formation.
It is important to note that collateral arteries often re-
gress once the shear stimulus has ceased. This process
called ‘pruning’ finally yields few large caliber collateral ar-
teries instead of a high number of small anastomoses [29].
In summary, the current understanding is that collat-
eral growth (called arteriogenesis) happens via a remod-
eling process of pre-existing small collaterals (collateral
remodeling). It differs from angiogenesis, the growth of
new capillary vessels, which is induced by ischemia. Col-
lateral growth, in contrast, is induced by fluid shear
stress in preformed collateral vessels caused by a pres-
sure gradient between the area proximal to a coronary
stenosis and the low-pressure post-stenotic area. The
shear stress on endothelial cells stimulates the produc-
tion of nitric oxide and MCP-1, leading to an attraction
of monocytes that play a key role in orchestrating collat-
eral remodeling, including attraction of endothelial pro-
genitor cells [30].
Clinical significance of coronary collaterals
The clinical relevance has been disputed repeatedly
since the anastomoses are often incapable of restoring
flow to normal levels [31]. In fact, the presence of col-
laterals was sometimes even assumed to signify a wors-
ening prognosis [20].
In the setting of an acute infarction, the relevance of
coronary collaterals has been shown in preserving myocar-
dial function [32], limiting infarct size [33], and positively
influence post-infarct remodeling [34]. Increased collateral
flow was also associated with less need for intra-aortic bal-
loon pumping post-percutaneous coronary intervention
(PCI) and better myocardial blush grade [35]. The pres-
ence of collaterals also appears to reduce mortality in pa-
tients, primarily due to a lower frequency of cardiogenic
shock [36]. Such observations support the view thatcollateral flow is a modifying factor, capable of alleviating
the deleterious effects of atherosclerosis on cardiovascular
morbidity and mortality.
To date, 12 studies have investigated the effect of collat-
erals on mortality. The first of these studies was published
in 1971 in the New England Journal of Medicine [37]. Only
three of these trials demonstrated a clear benefit for collat-
erals. This inconsistency did not actually help to resolve
the dispute [2]. The inconsistency is partially explainable
by the method of collateral assessment used in most of the
studies; collaterals were ‘qualified’ visually during the cor-
onary angiography [38]. This represents a rather crude ap-
proach. Intracoronary flow or pressure-based methods
(collateral flow index) using a pressure or Doppler sensor
tipped guide wire are more accurate [3]. The relevance of
the collateral circulation in case of a chronic total occlu-
sion of a coronary artery with normal left ventricular func-
tion is fairly obvious. There are even extreme examples of
patients with left main artery occlusion or three-vessel oc-
clusion with only mild symptoms [39]. Beside this anec-
dotal evidence, a pooled analysis of the above mentioned
12 studies (including 6,529 patients) clearly showed that,
overall, well developed collaterals are associated with a re-
duced mortality [40]. On average, the mortality was re-
duced by about 35% (Figure 3).
Even though collaterals seem to have a protective effect
balancing all the available evidence, they have been found
to be associated with a higher risk for restenosis. A meta-
analysis of 7 studies recruiting a total of 1,425 patients
showed that patients with good collateralization have a
40% higher risk of restenosis as compared with patients
with poor collateralization [41]. However, whether this as-
sociation is causal or whether collaterals just present a risk
marker is unclear. It could be an indication for the func-
tion of collaterals that prevent sufficient flow through the
stented vessel. Potentially, collaterals would have been able
to supply the subtended myocardium alone in these situa-
tions, rendering stenting unnecessary. Regardless, collat-
erals seem to be a useful and easily available marker on an
individual patient level for the clinical decision-making
process. In patients with better developed collaterals, car-
diologists should try to reduce the risk of restenosis by
using drug-eluting instead of bare-metal stents, or by pre-
scribing cilostazol [42,43].
Therapeutic potential
Multiple strategies to enhance collateral function have
been tested (Table 1). The important role of shear stress
and of monocytes have both been used as targets for
the therapeutic induction of collaterals. Granulocyte-
macrophage colony-stimulating factor (GM-CSF) and
granulocyte colony-stimulating factor (G-CSF) are
growth factors that increase monocyte numbers and they
have both shown to improve collateral function [44-46].
Figure 3 Forest plot illustrating the results of a meta-analysis of all studies that have assessed the association between the degree of
collateralization and mortality [13]. 95% CI, 95% confidence interval; CCC, coronary collateral circulation; RR, relative risk.
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the number but also on the gene expression profile of
monocytes, a further mechanism is the release of endo-
thelial progenitor cells from the bone marrow [46]. An-
other therapeutic option is to increase shear stress via
external counterpulsation [47] or via physical exercise
[48]; both strategies have demonstrated an effect on collat-
eral function. External counterpulsation (ECP) can be
regarded as a simulation of physical exercise in that it in-
creases shear forces on endothelial cells. It has repeatedly
been shown to reduce symptoms in patients with angina
pectoris but the mechanism of action has remained un-
known for years. The first controlled trial in a group of
patients with coronary artery disease undergoing a 30-hTable 2 Factors that have been tested to improve collateral c
Method (references) Positive effecta Application
Exercise [50, 51] Yes
External counterpulsation [47] Yes
GM-CSF [45,52] Yes Intracoronary, subcu
G-CSF [44] Yes Subcutaneous
Dipyridamole [53] Yes
VEGF [54] No Intracoronary
FGF4 (adenovirus) [55] No Intracoronary
aBased on a random effects meta-analysis model if more than one study.
CFI, collateral flow index; FGF4, fibroblast growth factor 4; G-CSF, granulocyte colony
(GM-CSF); VEGF, vascular endothelial growth factor.program of high-pressure ECP (300 mmHg) and in a
group undergoing sham ECP at 80 mmHg inflation pres-
sure has demonstrated a relevant improvement of the col-
lateral function (CFI) between baseline and follow-up at 4
weeks [47].
Another promising means to increase collateral artery
growth is heart rate reduction using ivabradine. Bradycar-
dia is known to be associated with better collateralization
(Table 1), probably because, due to prolongation of the
diastole, the lower heart rate increases the endothelial
shear stress. Experimental studies indicated a benefit of
ivabradine on collateral growth [49]. A clinical study
to test this concept in human is currently underway
(clinicaltrials.gov identifier NCT01039389); Table 2.irculation
Remarks
No randomized data, increase in CFI.
One randomized controlled trial (RCT), observational studies,
increase in CFI, improvement of angina symptoms
taneous Two small RCTs (n = 21, n = 12). Stopped early because of
potential plaque destabilization. Increase in CFI.
One small randomized trial (n = 52). Increase in CFI.
Very small trial (n = 30); angiographic collateral assessment,
which is not very accurate
No difference in angina symptoms or exercise tolerance
No change in exercise tolerance
-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor
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Coronary collateral arteries serve as conduits that bridge
severe stenosis or connect a territory supplied by one epi-
cardial artery with that supplied by another. They can be
recruited if required. While coronary collaterals provide
substantial blood flow to the resting heart, they are often
insufficient during increased myocardial oxygen demand
(for example, exercise). Collateral arteries can reduce in-
farct size, the risk for post-infarct complications and they
can also reduce mortality. Therefore, we have a consider-
able interest in developing methods to stimulate collateral
growth. Besides known triggers of tangential shear stress
and the presence of bone-marrow-derived mononuclear
cells for collateral growth, first clinical proof-of-concept
trials have demonstrated that collateral growth can be
promoted therapeutically by physical exercise, external
counterpulsation and certain growth factors and cytokines
(G-CSF and GM-CSF).
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